What happened
On October 5, 2026, the FDA updated an existing recall notice for certain infusion sets used with the BD Alaris Pump Module model 8100. The update adds affected products, current instructions and revised information about how the sets perform. It does not describe a newly discovered injury in October.
The concern is that fluid or medicine may be delivered less accurately than previously disclosed, particularly when the programmed rate is very low or the bolus volume is small. In those circumstances, the setting displayed on the pump may not accurately reflect what a patient receives. The FDA identifies this as its most serious type of recall, a classification of the potential hazard rather than a statement that serious injuries have occurred.
Why it matters
Before this update, facilities had an existing recall notice; they now have an expanded affected-product list, revised performance information and current directions for handling the sets. A delivery difference that might seem small can matter when the intended infusion or bolus is itself small. The practical change is therefore to identify the relevant sets, remove those the instructions say to discard, and review guidance for other affected configurations.
The recall does not mean every Alaris pump is unusable. Nor does the absence of reported serious injuries or deaths as of August 19 remove the need to follow the current instructions: the FDA’s concern is the potential consequence of an inaccurate infusion.
Evidence
The FDA says restrictive features in some sets can contribute to under- or over-infusion, delayed blockage alarms and inaccurate bolus delivery. These problems may not be obvious from the programmed setting, and a change in a patient’s condition may be difficult to recognize as an infusion-delivery problem.
The agency directs facilities to identify and discard discontinued sets, choose appropriate alternatives, and review the performance information for other affected configurations. As of August 19, 2026, BD had reported no serious injuries or deaths associated with the issue. That is a reporting status at a stated cutoff, not evidence that inaccurate delivery could not cause serious harm.
What remains unknown
The notice does not establish how many patients may have received inaccurate infusions or quantify the risk across every affected set and pattern of use. Those gaps prevent a single estimate from describing any facility’s exposure. Facilities need the affected-product details and customer instructions to determine which sets they hold and which directions apply.
Who may be affected
U.S. facilities using the specified pump and infusion sets, and the patients receiving infusions through them. The accuracy concern is especially consequential for teams caring for neonates, children and critically ill patients who receive small-volume infusions.
AXIONOVA connection
This is a healthcare-device reliability issue, not a finding about whether the medicine being infused works. The distinction that matters is between the pump and the particular disposable set attached to it: facilities need to identify discontinued affected sets and use the FDA-linked instructions to assess other affected configurations.
What ALETHA can explain
Aletha can explain the difference between the pump and its disposable infusion set, why an error matters more when the intended delivery is small, and how the FDA’s most-serious recall classification differs from a count of reported injuries.
Action posture
Urgent official safety direction: FDA's current instructions call for immediate identification and disposal of discontinued affected sets by facilities using them.